

Subject: Parenteral Antibiotics for the Treatment of Lyme Disease

Document #: MED.00013

Status: Revised

Publish Date: 06/28/2023

Last Review Date: 05/11/2023

Description/Scope

This document addresses the use of parenteral antibiotics (i.e., intravenous and intramuscular) for the treatment of Lyme disease.

Position Statement

Medically Necessary:

A course of up to 4 weeks of intravenous (IV) antibiotic therapy is considered **medically necessary** for individuals with Lyme disease meeting ANY of the following criteria:

- Myocarditis associated with second- or third-degree atrioventricular block, or with first-degree heart block when the PR interval is prolonged to 300 milliseconds or greater; **or**
- Persistent or recurrent joint swelling (that is, arthritis) after an initial 1 month trial of oral antibiotics; **or**
- Acute or chronic neurological disease affecting the central or peripheral nervous system, including ANY of the following:
 - Meningitis; **or**
 - Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis; **or**
 - Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy; **or**
 - Encephalomyelitis; **or**
 - Encephalopathy.

And antibiotic used is:

- Ceftriaxone (Rocephin[®]), cefotaxime (Claforan[®]), or Penicillin G; **or**
- Azithromycin (Zithromax[®]) in individuals with betalactam allergy or intolerance.

Investigational and Not Medically Necessary:

Intravenous (IV) antibiotic therapy for individuals with Lyme disease is considered **investigational and not medically necessary** when criteria are not met, including when the following IV drugs are used:

- Carbapenems (for example, doripenem, ertapenem, imipenem, meropenem); **or**
- First-generation cephalosporins (for example, cefazolin); **or**
- Fluconazole; **or**
- Fluoroquinolones (for example, levofloxacin, moxifloxacin).

Other indications for intravenous (IV) antibiotic therapy for Lyme disease are considered **investigational and not medically necessary**, including, but not limited to any of the following:

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

- Prophylactic treatment of individuals who have reported a tick bite but have no clinical findings suggestive of Lyme disease; **or**
- Treatment of individuals with systemic symptoms without serologic or cerebrospinal fluid (CSF) studies confirming Lyme disease; **or**
- Treatment of chronic fatigue syndrome or fibromyalgia attributed to Lyme disease; **or**
- Initial treatment of Lyme arthritis without coexisting neurological symptoms; **or**
- Treatment of persistent Lyme-associated arthritis after 2 prior courses of antibiotic therapy; **or**
- Treatment of “post-Lyme disease” syndrome; **or**
- Repeat or prolonged courses (greater than 4 weeks) of intravenous antibiotics.

Intramuscular antibiotics as a treatment of any aspect of Lyme disease are considered **investigational and not medically necessary**.

Rationale

A diagnosis of Lyme disease requires appropriate epidemiologic data, supporting clinical observation (including exposure to ixodid ticks in an endemic area), and supporting laboratory findings. However, over-diagnosis and over-treatment of Lyme disease is common (American College of Rheumatology, 1993; Hu, 1993; Steere, 1993). Intravenous antibiotic therapy in individuals with presumed Lyme disease may be inappropriately recommended in the following situations: an incorrect diagnosis; prolonged or repeated courses of IV antibiotics; and use of IV antibiotics when oral antibiotics are adequate. An incorrect diagnosis of Lyme disease includes those individuals with positive serologies without characteristic signs or symptoms of Lyme disease, or those with non-specific symptoms, but with no known exposure to ticks in an endemic area, or those without supporting serologic evidence.

Published literature suggests that IV antibiotic therapy should be limited to those individuals with objective and laboratory evidence of neuroborreliosis, those individuals with carditis and some degree of heart block, or in those with well-documented severe Lyme arthritis that does not respond to initial oral antibiotic therapy (Pachner, 1995; Rahn, 1991; Sigal, 1992 and 1995; Steere, 1997). Multiple randomized controlled studies, as well as reviews, of long-term antibiotic treatment for Lyme disease have failed to show a sustained positive therapeutic effect (Dattwyler, 1997; Fallon, 2007; Halperin, 2007a; Kaplan, 2003; Krupp, 2003; Oksi, 2007; Wormser, 2006).

In contrast to this body of data is a longitudinal cohort study of 158 subjects with significant neuropsychiatric symptoms of at least 3 months duration and laboratory-confirmed Lyme disease (Stricker, 2011). Subjects were treated with long-term IV ceftriaxone. The dose, frequency, and length of treatment were not standardized, but were left to the discretion of the treating physician. Subjects were categorized into five groups based on length of treatment: (1) 1-4 weeks (n=32); (2) 5-8 weeks (n=33); (3) 9-12 weeks (n=28); (4) 13-24 weeks (n=37); and (5) 25-52 weeks (n=28). Symptom outcomes were measured by a questionnaire developed by the investigators that evaluated three major categories including pain, neurologic function, and general symptoms. Primary outcomes were improvement in fatigue, cognition, myalgia, and arthralgia using the measurement tool. Baseline measures indicated significant variation in the degree of symptom severity, but the authors note that this variation reflected real-world presentation of Lyme neuroborreliosis. The results show that arthralgias were significantly improved during the 1-4 week treatment period, (p=0.04) but that no significant improvements were noted in any of the other time periods. Both myalgias and fatigue were significantly improved during the 5-8, 13-14, and 25-52 week periods (p=0.03, p=0.01, and p=0.01, respectively). Cognition was only significantly improved in the 25-52 week

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

timeframe ($p=0.02$). No data were provided regarding the impact of the different dosing or treatment protocols. These results are very interesting, and provide some data to indicate that longer-length treatment has differential impact on various symptom categories. However, the uncontrolled nature of this study, as well as the lack of standardization with regard to treatment protocol and dosing, the use of an unvalidated outcome tool, and finally, the small sample size of each group do not allow wider generalization of these results.

In 2007, the American Academy of Neurology published a practice parameter that specifies that “prolonged courses of antibiotics do not improve the outcome of post-Lyme syndrome, are potentially associated with adverse events, and are therefore not recommended (Level A recommendation).” This statement continues to be valid as noted in the 2021 recommendations noted below.

A biostatistical review published by DeLong and colleagues concludes that the results of the four NIH-sponsored randomized controlled trials most frequently cited to demonstrate the ineffectiveness of long-term antibiotic therapy for Lyme disease are significantly flawed, and that the conclusions drawn by their authors are unfounded (2012). The authors evaluate the methodology and results used by Fallon (2008), Kaplan (2003), Klemmner (2001), and Krupp (2003) in a systematic manner. Overall, DeLong indicates that none of the trials were designed to demonstrate non-inferiority of long-term antibiotic therapy. Furthermore, the studies had methodological flaws such as inadequate power due to small sample sizes, insufficient data on drop-outs, inappropriate combination of data, and use of an end point marker not widely recognized by the clinical community. In one case, they assert that the conclusions by Fallon et al. stating that the positive finding regarding improvement in fatigue measures was biased due to unblinding, was unsubstantiated. DeLong concludes that, “the inability of these trials to demonstrate a statistically significant finding provides neither proof of the absence of a clinically meaningful treatment effect nor evidence that patients with persistent symptoms suffer from a post-infectious syndrome.” While many of DeLong’s points are technically correct, the authors offer no evidence that repeated or long-term antibiotics are actually effective in ameliorating symptoms experienced by individuals after completion of currently recommended (IDSA) antibiotic therapy of Lyme disease. The evidence of improved net health outcomes from long-term antibiotic therapy for the treatment of Lyme disease remains insufficient. Additional evidence from well-designed, properly conducted and analyzed trials is needed to understand the balance of benefits and harms from long-term antibiotic therapy before such a strategy can be considered medically necessary.

In 2012, Fallon and colleagues published an article reappraising the available clinical trial data addressing what they term “post-treatment Lyme disease syndrome.” As with the DeLong article, Fallon discusses a list of methodological flaws in the Klemmner report (2001), including accuracy of the Lyme diagnosis, failure to control for pre-treatment disease severity, Klemmner’s statistical analyses, and a lack of consideration for the adverse effects of long-term antibiotic therapy. Klemmner has disputed these criticisms. A 2014 guideline from the International Lyme and Associated Diseases Society (ILADS) recommends use of long-term antibiotics, but its authors acknowledge that this is based on very low-quality evidence. Guidelines from the IDSA, ANA, and ACR do not support use of long-term antibiotics.

In 2019, Berende and others published the results of the Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) trial, a randomized, placebo-controlled study involving 239 subjects with persistent Lyme disease. All subjects received a 2-week open-label regimen of intravenous ceftriaxone before the 12-week blinded oral regimen involving doxycycline, clarithromycin/hydroxychloroquine, or placebo. After 14 weeks, no differences between the treatment arms were reported with regard to performance on the cognitive domains ($p=0.49-0.82$). At follow-up, no additional treatment effect or difference between groups was found at any time point ($p=0.35-0.98$ and $p=0.37-0.93$,

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

respectively). The authors concluded, “This study provides Class II evidence that longer-term antibiotics in patients with borreliosis-attributed persistent symptoms does not increase cognitive performance compared to shorter-term antibiotics.”

In 2020 the Association of Scientific Medical Societies (AWMF) published their guidelines for diagnosis and treatment in neurology. Their key recommendations were:

- A suspected clinical diagnosis of neuroborreliosis (cranial nerve deficits, meningitis/meningoradiculitis, encephalomyelitis) can be confirmed by the detection of inflammatory changes in cerebrospinal fluid linked to *Borrelia*-specific intrathecal antibody synthesis.
- Serological testing should only be conducted if there is sufficient clinical suspicion. ↑↑ (consensus 10/13)
- The following antibiotics should be used to treat early and late Lyme neuroborreliosis: doxycycline, ceftriaxone, cefotaxime, penicillin G. ↑↑ (consensus 9/13)
- Antibiotic treatment should last 14 days (early Lyme borreliosis) or 14–21 days (late Lyme borreliosis). ↑↑ (strong consensus 13/13)
- Estimation of treatment success should be based on the clinical symptoms. ↑↑ (strong consensus 12/12)

The Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR) published clinical practice guidelines for the prevention, diagnosis, and treatment of Lyme disease (Lantos, 2021). Regarding the use of IV antibiotics for the treatment of Lyme disease, the guidelines state the following:

XIII. What are the preferred antibiotic regimens for the treatment of acute neurologic manifestations of Lyme disease without parenchymal involvement of the brain or spinal cord?

Recommendation

1. In patients with Lyme disease–associated meningitis, cranial neuropathy, radiculoneuropathy, or with other peripheral nervous system (PNS) manifestations, we recommend using IV ceftriaxone, cefotaxime, penicillin G, or oral doxycycline over other antimicrobials (strong recommendation, moderate-quality evidence). Comment: Decisions about the choice of antibiotic among these, including the route of administration, should primarily be made based on individual factors such as side effect profile, ease of administration, ability to tolerate oral medication, and concerns about compliance unrelated to effectiveness. Treatment route may be changed from IV to oral during treatment. The preferred antibiotic duration is 14-21 days.

XIV. Should patients with Lyme disease-related parenchymal involvement of the brain or spinal cord be treated with oral or IV antibiotics?

Recommendation

1. In patients with Lyme disease-associated parenchymal involvement of the brain or spinal cord, we recommend using IV over oral antibiotics (strong recommendation, moderate-quality evidence).

XIX. What are the preferred antibiotic regimens for the treatment of Lyme carditis?

Recommendations

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

1. In outpatients with Lyme carditis, we suggest oral antibiotics over IV antibiotics (weak recommendation, very-low-quality evidence).
2. In the hospitalized patient with Lyme carditis, we suggest initially using IV ceftriaxone over oral antibiotics until there is evidence of clinical improvement and then switching to oral antibiotics to complete treatment (weak recommendation, very-low-quality evidence).
3. For the treatment of Lyme carditis, we suggest 14-21 days of total antibiotic therapy over longer durations of treatment (weak recommendation, very-low-quality evidence). Comment: Oral antibiotic choices for Lyme carditis are doxycycline, amoxicillin, cefuroxime axetil, and azithromycin.

XXII. What are the preferred antibiotic regimens for the initial treatment of Lyme arthritis?

Recommendation

1. For patients with Lyme arthritis, we recommend using oral antibiotic therapy for 28 days (strong recommendation, moderate-quality evidence).

XXIII. What are the approaches to patients in whom Lyme arthritis has not completely resolved?

Recommendations

1. In patients with Lyme arthritis with partial response (mild residual joint swelling) after a first course of oral antibiotic, we make no recommendation for a second course of antibiotic vs observation (no recommendation, knowledge gap). Comment: Consideration should be given to exclusion of other causes of joint swelling than Lyme arthritis, medication adherence, duration of arthritis before initial treatment, degree of synovial proliferation vs joint swelling, patient preferences, and cost. A second course of oral antibiotics for up to 1 month may be a reasonable alternative for patients in whom synovial proliferation is modest compared with joint swelling and for those who prefer repeating a course of oral antibiotics before considering IV therapy.
2. In patients with Lyme arthritis with no or minimal response (moderate to severe joint swelling with minimal reduction of the joint effusion) to an initial course of oral antibiotic, we suggest a 2- to 4-week course of IV ceftriaxone over a second course of oral antibiotics (weak recommendation, low-quality evidence).

XXIV. How should postantibiotic (previously termed antibiotic refractory) Lyme arthritis be treated?

Recommendation

1. In patients who have failed 1 course of oral antibiotics and 1 course of IV antibiotics, we suggest a referral to a rheumatologist or other trained specialist for consideration of the use of disease modifying antirheumatic drugs (DMARDs), biologic agents, intra-articular steroids, or arthroscopic synovectomy (weak recommendation, very-low-quality evidence). Comment: Antibiotic therapy for longer than 8 weeks is not expected to provide additional benefit to patients with persistent arthritis if that treatment has included 1 course of IV therapy.

XXV. Should patients with persistent symptoms following standard treatment of Lyme disease receive additional antibiotics?

Recommendation

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

1. For patients who have persistent or recurring nonspecific symptoms such as fatigue, pain, or cognitive impairment following recommended treatment for Lyme disease, but who lack objective evidence of reinfection or treatment failure, we recommend against additional antibiotic therapy (strong recommendation, moderate-quality evidence). Comment: Evidence of persistent infection or treatment failure would include objective signs of disease activity, such as arthritis, meningitis, or neuropathy.

It should be noted that the majority of these recommendations are supported by very low to moderate quality evidence, highlighting an overall lack of high-quality data to demonstrate the benefits and harms of any treatment approach, including long-term (greater than 1 month) IV antibiotic therapy. That said, in the absence of high-quality empirical evidence, the expert, informed opinion expressed by the IDSA, AAN and ACR in the 2021 guideline, backed by the cited data, represents the prevailing consensus of the expert practicing community responsible for the treatment of individuals with Lyme disease.

Background/Overview

Lyme disease is a multisystem inflammatory disease caused by the spirochete *Borrelia burgdorferi* and transmitted by the bite of an infected ixodid tick endemic to Northeastern, North Central, and Pacific coastal regions of the United States. The disease is characterized by stages, beginning with localized infection of the skin (erythema migrans), followed by dissemination to many sites. Manifestations of early disseminated disease may include lymphocytic meningitis, facial palsy, painful radiculoneuritis, atrioventricular nodal block, or migratory musculoskeletal pain. Months to years later, the disease may be manifested by intermittent oligoarthritis (particularly involving the knee joint), chronic encephalopathy, spinal pain, or distal paresthesias. While most manifestations of Lyme disease can be adequately treated with oral antibiotics, intravenous (IV) antibiotics are indicated in some individuals with neurologic involvement or atrioventricular heart block. However, over-diagnosis and over-treatment of Lyme disease is common due to its nonspecific symptoms, a lack of standardization of serologic tests, and difficulties in interpreting serologic test results. In particular, individuals with chronic fatigue syndrome or fibromyalgia are commonly misdiagnosed as possibly having Lyme disease and undergo inappropriate IV antibiotic therapy.

Risk factors in contracting Lyme disease center on people's exposure to outside environments in areas where Lyme disease occurs. Such activities include working in areas surrounding tick-infested woods and overgrown brush and in outside occupations. Additionally, people who spend time outside or participate in leisure activities such as hunting, fishing, hiking, or camping are at high risk for Lyme disease. Any of these activities bring these participants into areas where ticks may be present.

The following paragraphs describe the various manifestations of Lyme disease that may prompt therapy with IV antibiotics (IDSA, 2006).

Neurologic Manifestations of Lyme Disease (Neuroborreliosis)

Lymphocytic meningitis, characterized by head and neck pain, may occur during the acute disseminated stage of the disease. Analysis of the cerebrospinal fluid (CSF) is indispensable for the diagnosis of Lyme meningitis. If the individual has Lyme disease, the CSF will show a lymphocytic pleocytosis (presence of too many cells) with increased levels of protein. Intrathecal production of antibodies directed at spirochetal antigens is typically present.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

A normal CSF analysis is strong evidence against Lyme meningitis. Treatment with a 2- to 4-week course of IV antibiotics, typically ceftriaxone or cefotaxime, is recommended.

Cranial neuritis, most frequently Bell's palsy, may present early in the course of disseminated Lyme disease, occasionally prior to the development of antibodies, such that a Lyme disease etiology may be difficult to rule in or out. While Bell's palsy typically resolves spontaneously with or without treatment with oral antibiotics, some physicians have recommended a lumbar puncture and a course of IV antibiotics if pleocytosis in the CSF is identified, primarily as a prophylactic measure to prevent further neurologic symptoms.

A subacute encephalopathy may occur months to years after disease onset, characterized by subtle disturbances in memory, mood, sleep, or cognition accompanied by fatigue. These symptoms may occur in the absence of abnormalities in the electroencephalogram (EEG), magnetic resonance imaging (MRI), or CSF. In addition, the symptoms are nonspecific and overlap with fibromyalgia and chronic fatigue syndrome. Thus, diagnosis of Lyme encephalopathy may be difficult and may be best diagnosed with a mental status exam or neuropsychological testing. However, treatment with IV antibiotics is generally not indicated unless CSF abnormalities are identified.

Much rarer, but of greater concern, is the development of encephalomyelitis, characterized by spastic paraparesis, ataxias, cognitive impairment, bladder dysfunction, and cranial neuropathy. CSF examination reveals a pleocytosis and an elevation in protein. Selective synthesis of anti-spirochetal antigens can also be identified. A course of IV antibiotics with 3 to 4 weeks of ceftriaxone is suggested when CSF abnormalities are identified.

A variety of peripheral nervous system manifestations of Lyme disease have also been identified. Symptoms of peripheral neuropathy include paresthesias, or radicular pain with only minimal sensory signs. Individuals typically exhibit electromyographic (EMG) or nerve conduction velocity abnormalities. CSF abnormalities are usually seen only in those individuals with a coexistent encephalopathy.

Cardiac Manifestations of Lyme Disease

Lyme carditis may appear during the early dissemination stage of the disease; symptoms include atrioventricular heart block, tachyarrhythmias, and myopericarditis. Antibiotics are typically given, although no evidence proves that this therapy hastens the resolution of symptoms. Both oral and IV regimens have been advocated. Intravenous regimens are typically used in individuals with a high degree atrioventricular block or a PR interval on the electrocardiogram (EKG) of greater than 0.3 seconds (300 milliseconds). Individuals with milder forms of carditis may be treated with oral antibiotics.

Lyme Arthritis

Lyme arthritis is a late manifestation of infection and is characterized by an elevated IgG response to *B. burgdorferi* and intermittent attacks of oligoarticular arthritis, primarily in the large joints such as the knee. Individuals with Lyme arthritis may be successfully treated with a 30-day course of oral doxycycline or amoxicillin, but care must be taken to exclude simultaneous central nervous system (CNS) involvement, requiring IV antibiotic treatment. In the small subset of individuals who do not respond to oral antibiotics, an additional 30-day course of oral or IV antibiotics may be recommended.

Fibromyalgia and Chronic Fatigue Syndrome

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

Fibromyalgia and chronic fatigue syndrome are the diseases most commonly confused with Lyme disease. Fibromyalgia is characterized by musculoskeletal complaints, multiple trigger points, difficulty in sleeping, generalized fatigue, headache, or neck pain. The joint pain associated with fibromyalgia is typically diffuse, in contrast to Lyme arthritis, which is characterized by marked joint swelling in one or a few joints at a time, with few systemic symptoms. Chronic fatigue syndrome is characterized by multiple subjective complaints, such as overwhelming fatigue, difficulty in concentration, and diffuse muscle and joint pain. In contrast to Lyme disease, both of the above conditions lack joint inflammation, have normal neurological test results, or have test results suggesting anxiety or depression. Neither fibromyalgia nor chronic fatigue syndrome has been shown to respond to antibiotic therapy.

Definitions

Arthritis: Inflammation of the joints.

Carditis: Inflammation of the heart.

Chronic fatigue syndrome: A condition of prolonged and severe tiredness or weariness (fatigue) that is not relieved by rest and is not directly caused by other conditions.

Fibromyalgia: A common condition characterized by widespread pain in joints, muscles, tendons, and other soft tissues.

Lyme disease: A disease caused by the bacteria *Borrelia burgdorferi*, which is transmitted through the bite of the deer tick (*Ixodes scapularis*).

Neurological involvement: When a medical condition involves the nervous system.

PR interval: A portion of an electrocardiogram that measures the distance in time (in seconds) from the beginning of the P wave to the beginning of the R wave. The normal PR interval duration range is from 0.12 sec – 0.20 sec. Longer PR intervals may indicate electrical conduction problems within the heart.

Prophylactic antibiotic therapy: The use of antibiotic medications in order to prevent infection when no infection exists.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services may be Medically Necessary when criteria are met for treatment of Lyme disease:

CPT

96365

Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

| | |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour |
| 96367 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour |
| 96368 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion |

HCPCS

| | |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| J0456 | Injection, azithromycin, 500 mg |
| J0696 | Injection, ceftriaxone sodium, per 250 mg |
| J0698 | Injection, cefotaxime sodium, per gm |
| J2540 | Injection, penicillin G potassium, up to 600,000 units [IV] |
| S9494 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem |
| S9497 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 3 hours |
| S9500 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy; once every 24 hours |
| S9501 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy, once every 12 hours |
| S9502 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy, once every 8 hours |
| S9503 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy, once every 6 hours |
| S9504 | Home infusion therapy, antibiotic, antiviral, or antifungal therapy, once every 4 hours |

ICD-10 Diagnosis

| | |
|---------------|--------------|
| A69.20-A69.29 | Lyme disease |
|---------------|--------------|

When services are Investigational and Not Medically Necessary for treatment of Lyme disease:

For the procedure and diagnosis codes listed above when criteria are not met, or when the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

When services also are Investigational and Not Medically Necessary for treatment of Lyme disease:

CPT

| | |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 96372 | Therapeutic, prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular [when specified as intramuscular antibiotic injection] |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

HCPCS

| | |
|-------|----------------------------------------------------------------------------------|
| J0558 | Injection, penicillin G benzathine and penicillin G procaine, 100,000 units [IM] |
| J0561 | Injection, penicillin G benzathine, 100,000 units [IM] |
| J0690 | Injection, cefazolin sodium, 500 mg |
| J0743 | Injection, cilastatin sodium; imipenem, per 250 mg |
| J1267 | Injection, doripenem, 10 mg |
| J1335 | Injection, ertapenem sodium, 500 mg |
| J1450 | Injection, fluconazole, 200 mg |
| J1956 | Injection, levofloxacin, 250 mg |
| J2185 | Injection, meropenem, 100 mg |

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

| | |
|-------|---------------------------------------------------------------------|
| J2280 | Injection, moxifloxacin, 100 mg |
| J2510 | Injection, penicillin G procaine, aqueous, up to 600,000 units [IM] |

ICD-10 Diagnosis

| | |
|---------------|--------------|
| A69.20-A69.29 | Lyme disease |
|---------------|--------------|

References

Peer Reviewed Publications:

1. Berende A, Ter Hofstede HJM, Vos FJ, et al. Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis. *Neurology*. 2019; 92(13):e1447-e1455.
2. Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. *N Engl J Med*. 1997; 337(5):289-294.
3. DeLong AK, Blossom B, Maloney EL, Phillips SE. Antibiotic retreatment of Lyme disease in patients with persistent symptoms: a biostatistical review of randomized, placebo-controlled, clinical trials. *Contemp Clin Trials*. 2012; 33(6):1132-1142.
4. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. *Neurology*. 2008; 70(13):992-1003.
5. Fallon BA, Petkova E, Keilp JG, Britton CB. A reappraisal of the U.S. clinical trials of post-treatment Lyme disease syndrome. *Open Neurol J*. 2012; 6:79-87.
6. Halperin JJ. Prolonged Lyme disease treatment: enough is enough. *Neurology*. 2008; 70(13):986-987.
7. Hsu VM, Patella SJ, Sigal LH. "Chronic Lyme disease" as the incorrect diagnosis in patients with fibromyalgia. *Arthritis Rheum*. 1993; 36(11):1493-1500.
8. Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? *Neurology*. 2003; 60(12):1916-1922.
9. Klemmner MS, Baker PJ, Shapiro ED, et al. Treatment trials for post-Lyme disease symptoms revisited. *Am J Med*. 2013; 126(8):665-669.
10. Klemmner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N Engl J Med*. 2001; 345(2):85-92.
11. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. *Neurology* 2003; 60(12):1923-1930.
12. Oksi J, Nikoskelainen J, Hiekkänen H, et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. *Eur J Clin Microbiol Infect Dis*. 2007; 26(8):571-581.
13. Pachner AR. Early disseminated Lyme disease: Lyme meningitis. *Am J Med*. 1995; 98(4A):30S-43S.
14. Sigal LH. Early disseminated Lyme disease: cardiac manifestations. *Am J Med*. 1995; 98(4A):25S-29S.
15. Steere AC. Diagnosis and treatment of Lyme arthritis. *Med Clin North Am*. 1997; 81(1):179-194.
16. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. *JAMA*. 1993; 269(14):1812-1816.
17. Stricker RB, DeLong AK, Green CL, et al. Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease. *Int J Gen Med*. 2011; 4:639-646.

Government Agency, Medical Society, and Other Authoritative Publications:

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

1. Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Antibiotics for the neurological complications of Lyme disease. *Cochrane Database Syst Rev.* 2016;(12):CD006978.
2. Feder HM Jr, Johnson BJ, O’Connell S, et al.; Ad Hoc International Lyme Disease Group. A critical appraisal of “chronic Lyme disease”. *N Engl J Med.* 2007; 357(14):1422-1430.
3. Halperin JJ, Shapiro ED, Logigian E, et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* 2007a; 69(1):91-102.
4. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. *Neurology.* 2021; 96(6):262-273.
5. Myglund A, Ljøstad U, Fingerle V, et al.; European Federation of Neurological Societies. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. *Eur J Neurol.* 2010; 17(1):8-16, e1-4.
6. Rauer S, Kastenbauer S, Hofmann H, et al.; Consensus group. Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis. *Ger Med Sci.* 2020; 18:Doc03.

Websites for Additional Information

1. Centers for Disease Control and Prevention. Lyme disease Home Page. Reviewed: January 19, 2022. Available at: <http://www.cdc.gov/lyme/>. Accessed on April 27, 2023.
2. Centers for Disease Control and Prevention. Post-Treatment Lyme Disease Syndrome. Reviewed January 10, 2022. Available at: <http://www.cdc.gov/lyme/postLDS/index.html>. Accessed on April 27, 2023.

Index

Antibiotic Therapy
 Intravenous Antibiotic Therapy
 Lyme Disease

Document History

| Status | Date | Action |
|----------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Revised | 05/11/2023 | Medical Policy & Technology Assessment Committee (MPTAC) review. Revised MN criteria related to PR interval for myocarditis. Updated Rationale, References, and Websites sections. |
| Reviewed | 05/12/2022 | MPTAC review. Updated Websites section. |
| Reviewed | 05/13/2021 | MPTAC review. Updated Rationale, References, and Websites sections. |
| Reviewed | 08/13/2020 | MPTAC review. Updated References and Websites sections. |
| Reviewed | 11/07/2019 | MPTAC review. Updated Rationale and References sections. |
| Reviewed | 01/24/2019 | MPTAC review. |
| Reviewed | 02/02/2017 | MPTAC review. Updated Reference section. |
| Revised | 02/04/2016 | MPTAC review. Added a minor language revision in the position statement. Removed ICD-9 codes from Coding section. |
| Reviewed | 02/05/2015 | MPTAC review. Updated Rationale and Reference sections. |
| Reviewed | 02/13/2014 | MPTAC review. Updated Rationale and Reference sections. |

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Parenteral Antibiotics for the Treatment of Lyme Disease

| | | |
|----------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Reviewed | 02/14/2013 | MPTAC review. Deleted the term “vague” from the not medically necessary section. Updated Rationale, Background and Reference sections. |
| Revised | 02/16/2012 | MPTAC review. Added use of azithromycin to medically necessary position statement. Added use of carbapenems, first-generation cephalosporins, Fluconazole, and fluoroquinolones to investigational and not medically necessary section. Updated Rationale, Background and Coding sections. |
| Reviewed | 02/17/2011 | MPTAC review. Updated Coding and Reference sections. |
| Reviewed | 02/25/2010 | MPTAC review. |
| Revised | 02/26/2009 | MPTAC review. Updated medically necessary criteria regarding myocarditis. Updated Reference section. |
| | 01/01/2009 | Updated Coding section with 01/01/2009 CPT changes; removed 90765, 90766, 90767, 90768, 90772 deleted 12/31/2008. |
| Revised | 02/21/2008 | MPTAC review. Clarified type of Penicillin in medically necessary section. Added criteria for the diagnosis of acute or chronic neurological Lyme disease to medically necessary section. |
| Revised | 11/29/2007 | MPTAC review. Added cefotaxime and drug brand names to medically necessary statement. Added investigational and not medically necessary statement for when criteria are not met. The phrase “investigational/not medically necessary” was clarified to read “investigational and not medically necessary.” Updated Rationale, Coding and Reference sections. |
| Reviewed | 12/07/2006 | MPTAC review. Coding updated; removed CPT 90780, 90781, 90782 and HCPCS G0347, G0348, G0349, G0350 deleted 12/31/2005. |
| Revised | 12/01/2005 | MPTAC review. Revised document title to “Parenteral Antibiotics for the Treatment of Lyme Disease”. Removed position language regarding the use of oral antibiotics and laboratory testing; elaborated on the definition of neurological involvement in Medically Necessary section; added treatment of persistent arthritis after 2 prior courses of antibiotic therapy and treatment of “post-Lyme disease” syndrome as not medically necessary. |
| Revised | 07/14/2005 | MPTAC review. Revision based on Pre-merger Anthem and Pre-merger WellPoint Harmonization. |

| Pre-Merger Organizations | Last Review Date | Document Number | Title |
|---------------------------------|-------------------------|------------------------|---------------------------------|
| Anthem, Inc. | 4/27/2004 | MED.00013 | Lyme Disease Treatment |
| WellPoint Health Networks, Inc. | 9/23/2004 | 2.01.05 | Lyme Disease (Lyme Borreliosis) |

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.